ArticleIrish journal of medical science2026
Changes in statin therapy following discharge in those with cardiovascular disease in Ireland.
Article in Irish journal of medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionHigh-intensity statin (HIS) therapy is recommended for all patients with cardiovascular disease, yet many receive sub-optimal lipid-lowering therapy because of non-HIS prescribing or de-escalation in routine care. This study used data from the Irish ASPIRE (I-ASPIRE) survey to examine the frequency and reasons for HIS dose reduction in secondary prevention, and to assess how statin intensity influences LDL-cholesterol (LDL-C) target achievement.
methodsWe retrospectively analysed 669 patients with acute or chronic coronary heart disease recruited from cardiology inpatient wards and outpatient clinics at nine Irish centres, with follow-up 6-24 months after the index event. Statin intensity, LDL-C levels and secondary prevention target attainment were compared between patients on HIS and non-HIS at follow-up.
resultsAt a mean follow-up of 1.21 years, 64% (428/669) were prescribed HIS, and 21% (140/669) had lipid-lowering therapy down-titrated after discharge. Patients on HIS at follow-up had lower mean LDL-C than those on non-HIS (1.86 vs. 2.16 mmol/L; p < 0.005) and higher rates of guideline LDL-C target achievement. HIS was less frequently prescribed in patients with chronic cardiovascular disease than in those with acute disease (41% vs. 65%; p < 0.05), and more frequently among cardiac rehabilitation attendees (67% vs. 55%; p = 0.014). DISCUSSION: These findings show that de-escalation from high-intensity statins is frequent and associated with less favourable LDL-C profiles, identifying potentially avoidable loss of treatment intensity as a modifiable barrier to optimal lipid management in secondary prevention.
Indexed as
Identifiers
42766087What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.